SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's after-hours surge is fueled by better-than-expected earnings and strong Q4 guidance, particularly driven by AWS growth. Community discussions revolve around potential ATH and target prices, with many regretting not buying more, while some caution against greed and anticipate a pullback. The earnings beat, especially in cloud services, has reignited bullish sentiment around the stock.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple's earnings are driving significant discussion, with debates focusing on whether the results justify the company's high valuation and PE ratio. Community members are closely watching guidance for the next quarter, particularly regarding iPhone sales and growth in China. Some traders express concerns about overvaluation and are considering short positions, while others remain bullish, anticipating a continued climb towards higher price targets.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy ($MSTR) is trending following its Q3 earnings report, with community chatter focused on the company's significant earnings beat driven by its Bitcoin holdings. Despite the positive results, some investors express concern over the stock's price movement and the broader context of its business model, while others point to potential S&P 500 inclusion and analyst upgrades as bullish signals.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit's stock is trending following a strong earnings report, with revenue and EPS exceeding analyst expectations and user growth remaining solid. The community is buzzing about the potential for a continued rally towards previous highs, although some traders are wary of a possible pullback. Discussions also include the impact of AI and data licensing deals on Reddit's revenue streams, as well as a debate on the stock's valuation relative to its growth.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

RKT is trending as investors discuss the potential for a short squeeze following strong earnings and positive Q4 revenue guidance. Community members are highlighting the high short interest and upcoming catalysts like potential rate cuts and the integration of recent acquisitions. Some are closely watching for analyst upgrades and increased price projections amidst discussions of long-term growth potential in the housing market.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

LUMN is trending due to positive sentiment surrounding its AI connectivity fabric and recent partnerships, particularly with Palantir, fueling speculation about future government contracts. Community members are actively discussing the potential for a significant earnings beat and a re-rating as a tech company, while also weighing the company's debt against its growth prospects in the AI infrastructure space.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is trending due to a mix of community speculation and reactions to its recent earnings call. While some investors express concerns about the company's execution and guidance, others remain optimistic about its technology and potential in the AI and defense sectors, particularly noting its energy efficiency. Discussion also revolves around a recent $50 million investment and speculation regarding potential partnerships or a buyout, with some drawing comparisons to sector giants like NVDA.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest recent earnings and pipeline developments, with discussions focused on revenue guidance and the potential of their next-generation inhibitor. Community sentiment appears mixed, with some expressing confidence in management's vision and others concerned about market undervaluation and the ongoing CMS legal battle. Bullish investors are hoping for a breakout driven by strong execution and potential M&A activity.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Dexcom Inc

Dexcom ($DXCM) is trending amid concerns over the G7 product's quality and reliability, with some users reporting failures and inaccuracies, while others defend its performance and praise its features; this debate is amplified by a recent short report alleging safety issues with the device. Community discussions also revolve around the potential impacts of a CEO transition, manufacturing locations, and competition from Abbott on Dexcom's future growth and market position. Despite mixed sentiment, some investors express optimism, citing potential for a rebound and upcoming catalysts like new product releases.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

GSAT is trending amid speculation of a potential sale, with SpaceX named as a possible suitor, sparking community discussion around potential buyout prices and the involvement of key partners like Apple. Investors are also weighing the significance of Globalstar's n53 spectrum and potential deals with Amazon and Walmart. Some traders are expressing hope for a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Precision Oncology Approaches Drive $312B Market Transformation

Precision Oncology Approaches Drive $312B Market Transformation Precision Oncology Approaches Drive $312B Market Transformation PR Newswire VANCOUVER, Oct. 17, 2025 USA News Group News Commentary...

Nurix Therapeutics shares fell more than 6% in after-hours trading on Thursday after the biotech firm reported a wider quarterly loss and lower revenue, reflecting higher research spending and changes in collaborations.In the third fiscal quarter ended Aug. 31, the San Francisco–based company posted a net loss of $86.4 million, or $1.03 a share, versus a loss of $49 million, or $0.67 a share, a year earlier.&nbsp;Revenue dropped to $7.9 million from $12.6 million, with income from its collaboration with Sanofi down following the expiration of the initial research period for certain targets. The decrease was partly offset by a higher percentage of completion of performance obligations related to its partnership with Pfizer.Research and development costs increased to $86.1 million from $55.5 million a year ago, mainly due to higher clinical, manufacturing and consulting costs related to increased enrollment in ongoing studies and preparation for late-stage trials.Nurix said it plans to launch pivotal trials next year for its BTK degrader bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The program will include a single-arm study for potential accelerated approval and a randomized Phase 3 trial for full approval.The company reported $428.8 million in cash and marketable securities at the end of the quarter and said it had enough capital to continue funding its programs and development partnerships with Gilead, Sanofi and Pfizer.Oppenheimer maintained an 'Outperform' rating on Nurix Therapeutics after lowering its price target to $28 from $30 following its results. The brokerage said shares have rebounded as investors become more comfortable with the regulatory strategy for bexobrutideg, particularly its prospects for accelerated approval.Oppenheimer noted that Nurix has been having ongoing discussions with the FDA under the drug’s Fast Track designation, and while management has continued to say publicly that accelerated approval will be a review issue, changes in the company’s latest corporate presentation suggest the FDA is&nbsp;on board with the plan, the firm added.One user noted that research and development spending had “gone way up,” suggesting it could shorten the company’s cash runway, but added there was still time to buy before shares begin to move higher ahead of pivotal bexobrutideg data.<stembedurl>https://stocktwits.com/oaksapollo/message/631728185</stembedurl>Another user said they had increased their position in Nurix, adding that they plan to keep buying as long as the stock remains below $10, and argued that bexobrutideg alone justifies the company’s roughly $685 million market capitalization.<stembedurl>https://stocktwits.com/oaksapollo/message/630831468</stembedurl><a href="https://stocktwits.com/symbol/NRIX">Nurix’s stock</a> has declined 42% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nurix’s stock (NRIX) has declined 42% so far in 2025. (Photo credit: Getty Images)

Nurix Stock Falls After-Hours After Wider Q3 Loss; Oppenheimer Sees FDA Support For Bexo, Retail Buys The Dip

Oppenheimer cut its price target to $28 from $30 but kept a bullish view, citing FDA discussions and investor confidence in its Bexo program.

Equity

Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -22.62% and -57.71%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?

Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock?

Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates

KalVista Pharmaceuticals (KALV) delivered earnings and revenue surprises of -23.08% and -20.91%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Nurix Therapeutics jumped on Wednesday after the biotech company reported stronger-than-expected results for the second quarter (Q2), bolstered by payments related to development milestones with both Sanofi and Gilead Sciences.The <a href="https://stocktwits.com/symbol/NRIX">Nurix Therapeutics stock</a> rose 7.9% on Wednesday and climbed another 13.9% after-hours.The company reported a net loss of $0.52 per share for the quarter ended May 31, above analyst estimates of a loss of $0.74 per share.&nbsp;Nurix also recorded revenue of $44.1 million, exceeding estimates of $17.5 million.&nbsp;A large chunk of that came from a $30 million license payment from Sanofi and a $5 million milestone tied to a Gilead-supported clinical program.Spending also increased as the company pushed ahead with its lead drug candidates.&nbsp;Research and development costs climbed to $78.1 million, up from $48.9 million a year earlier, while administrative expenses rose to $14.3 million from $11.7 million.The company shared new data from an early-stage trial of bexobrutideg, a BTK degrader it’s developing for certain blood cancers.&nbsp;Among patients with relapsed or treatment-resistant chronic lymphocytic leukemia, the treatment showed a response rate of 80.9%, with no serious heart issues or other safety red flags reported.Nurix finished the quarter with $485.8 million in cash and investments. The figure doesn’t include an additional $19 million it received shortly after the quarter ended from its partners.Looking ahead, the company plans to start late-stage trials of bexobrutideg later this year.&nbsp;It’s also expecting more clinical updates from other programs in its pipeline, including NX-2127 and NX-1607.On Stocktwits, retail sentiment was ‘bullish’ amid ‘extremely high’ message volume.One user noted that Nurix’s Q2 loss of $0.52 per share came in about 30% better than analyst expectations, and added that the stock could see another strong session tomorrow.<stembedurl>https://stocktwits.com/LongTrainRunning/message/620401421</stembedurl>Nurix Therapeutics’ stock has declined 32.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nurix Therapeutics (NRIX) reported stronger-than-expected results for the second quarter/ Photo credit: Getty Images

Nurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead Payments

The company also shared promising early data from its blood cancer drug bexobrutideg and said it plans to begin late-stage trials later this year. 

Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Nurix Therapeutics (NRIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's  What You Should Know

The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 143.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?

Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Nurix Therapeutics Inc

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.98	--	--	N/A
Q3 '25	-$0.82	-$1.03	-26.01%	MISSED
Q2 '25	-$0.70	-$0.52	25.76%	BEAT
Q1 '25	-$0.76	-$0.67	12.06%	BEAT
Q4 '24	-$0.69	-$0.75	-9.31%	MISSED

NRIX
Nurix Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest NRIX News

NRIXNurix Therapeutics Inc